CD19 and acute lymphoblastic leukemia: Clinical trials evaluating multitargeted CAR-T cell therapy against ALL, such as single engineered CAR-T cells targeting both CD19 and CD22 and a combination of CAR-T cells with anti-CD19 and anti-CD20 to target each antigen independently, have yielded encouraging results (Huang et al., 2018).